uniQure N.V. (QURE)
NASDAQ:QURE

uniQure (QURE) Stock Price & Analysis

792 Followers

QURE Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$12.52 - $28.26
Previous Close$22.92
Volume311.02K
Average Volume (3M)703.53K
Market Cap$1.07B
Enterprise Value$771.41M
Total Cash (Recent Filing)$440.31M
Total Debt (Recent Filing)$138.72M
Price to Earnings (P/E)-8.5
Beta0.67
Next EarningsMar 15, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-2.68
Shares Outstanding46,815,109
R-Squared0.08
Standard Deviation0.20
10 Day Avg. Volume439,339
30 Day Avg. Volume703,535
Price to Book (P/B)2.89
Price to Sales (P/S)271.02
Price to Cash Flow (P/CF)2.90
P/FCF Ratio-9.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.56
Enterprise Value/Gross Profit1.55
Enterprise Value/Ebitda-7.11
Price Target Upside143.79% Upside
Rating ConsensusStrong Buy
Alpha0.01
Number of Analyst Covering11


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

QURE FAQ

What was uniQure’s price range in the past 12 months?
uniQure lowest stock price was $12.52 and its highest was $28.25 in the past 12 months.
    What is uniQure’s market cap?
    Currently, no data Available
    When is uniQure’s upcoming earnings report date?
    uniQure’s upcoming earnings report date is Mar 15, 2023 which is in 34 days.
      How were uniQure’s earnings last quarter?
      uniQure released its earnings results on Nov 02, 2022. The company reported -$1.02 earnings per share for the quarter, beating the consensus estimate of -$1.198 by $0.178.
        Is uniQure overvalued?
        According to Wall Street analysts uniQure’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does uniQure pay dividends?
          uniQure does not currently pay dividends.
          What is uniQure’s EPS estimate?
          uniQure’s EPS estimate is -$0.89.
            How many shares outstanding does uniQure have?
            uniQure has 46,815,110 shares outstanding.
              What happened to uniQure’s price movement after its last earnings report?
              uniQure reported an EPS of -$1.02 in its last earnings report, beating expectations of -$1.198. Following the earnings report the stock price went up 7.272%.
                Which hedge fund is a major shareholder of uniQure?
                Among the largest hedge funds holding uniQure’s share is Carlson Capital LP. It holds uniQure’s shares valued at 1M.

                  ---

                  uniQure Stock Smart Score

                  The uniQure stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  uniQure N.V.

                  uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Merus
                  LAVA Therapeutics
                  ProQR
                  Sangamo Biosciences

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis